On 17 October 2025, Samsung Biologics announced that its biosimilar operations will be spun off into a new holding entity, Samsung Epis Holdings, after the proposal was approved by shareholders at an Extraordinary General Meeting.
Following the spin-off, Samsung Biologics will focus on its contract development and manufacturing (CDMO) business, while Samsung Epis Holdings will become the parent company of the biosimilar unit, Samsung Bioepis, supporting its R&D and also exploring new growth opportunities including development of bio-platform technologies.
According to materials published by Samsung Biologics in advance of the Extraordinary General Meeting, the spin-off is partly driven by client concerns of potential conflicts of interest with a perception that Samsung Biologics was operating a competing biosimilar business to Samsung Bioepis. Another factor influencing the separation is valuation limitations due to differences between order-based (Samsung Biologics) and R&D-driven (Samsung Bioepis) models.
The spin-off is tentatively expected to take effect on 1 November 2025, with both entities to be relisted on the Korean Exchange on 24 November 2025.